Johnson Matthey


Taking a more cautious stance

19/11/20 -"Contrary to management, our view on the coming months is less enthusiastic. Calendar Q4 might see some higher inventory, also in the light of Brexit. However, we are not very optimistic for Q1 21, ..."

Pages
51
Language
English
Published on
19/11/20
You may also be interested by these reports :
25/11/20
Clariant plans to book CHF-70m of provisions in Q4 in order to finance a c.1,000 headcount cut by 2022. This measure is in addition to the ongoing ...

23/11/20
Wacker’s Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production ...

19/11/20
Contrary to management, our view on the coming months is less enthusiastic. Calendar Q4 might see some higher inventory, also in the light of Brexit. ...

19/11/20
JMAT’s management guides for a ‘materially’ better second half compared to the first half of this (business) year. We assume this is based on the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO